Media ReleasesBARD1 Life Sciences

View All BARD1 Life Sciences News


BARD1 life Sciences - Appendix 4C & Quarterly Activities Report


• Commercial progress:
-- hTERT receipts of $221k for the period compared to $184k for the previous quarter
-- EXO-NET® RUO evaluations progress with academic and industry partners
-- BARD1 autoantibody technology and data undergoing comprehensive review
• Solid R&D progress:
-- Proof-of-Concept (POC) achieved for SubB2M-based ELISA1 for ovarian cancer in feasibility studies
-- Promising exosome-based ovarian cancer test data released by collaborator University of Queensland (UQ) using EXO-NET for isolation of exosomes
-- Dr Greg Rice appointed as CSO2 to accelerate commercial development of diagnostic tests
• Corporate initiatives:
-- Capital raising of $18.4m from a Placement and Share Purchase Plan (SPP) strengthening proforma cash balance to $22m
• Cash position:
-- Net cash of $17.2m received from share placement and SPP
-- Cash balance of $20.4m as at 30 September 2021

Melbourne, Australia, 29 October 2021: BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company), today released its Appendix 4C and Quarterly Business Update for the quarter ended 30 September 2021.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.